Day Two: Wednesday July 26, 2017
REGISTRATION & COFFEE
Introduction and Summary
Biomarkers & Companion Diagnostics
Biomarkers in cancer immunotherapy: challenges and opportunities
Associate Scientific Director
The evolution of TKI-resistance in EGFR mutant NSCLC.
Matt NiederstInvestigator, Oncology Translational Research
Use of liquid biopsies for detection of biomarkers and resistance mechanisms in NSCLC
Associate Principal Scientist
Neratinib for treatment of Lung Cancers with Somatic HER2 Mutations
Vice President, Translational Medicine
Molecular Diagnosis of Lung Cancer: MODAplex Lung Panel concept.
Director, Molecular Pathology
MORNING REFRESHMENTS & SPEED NETWORKING
Genetic characterization of patients with advanced small cell lung cancer from circulating tumor DNA to identify predictive biomarkers
Director, Oncology Translational Medicine
An Approach to Conducting Dx-Driven Oncology Trials of Rare Patient Populations
Vice President, Diagnostics
LUNCH & NETWORKING
Amir Handzel Diagnostics and Personalized MedicineAstraZeneca
more to be announced..
Targeting Rare Oncogenic Kinases in Lung Cancer
Vice President, Research and Development
Targeting immune evasion and therapy resistance through selective Axl inhibition with BGB324
Clinical Development Officer
AFTERNOON REFRESHMENTS & NETWORKING
Overcoming Resistance in Precision Lung Cancer Treatment
Founder and Chief Scientific Officer
Targeted and Personalized Peptide Therapy to Treat Small Cell Lung Cancer
Chief Executive Officer
XMT-1536, a highly potent NaPi2b-targeted Dolaflexin® antibody-drug conjugate
Executive Director, External Scientific Affairs
SUMMARY & CLOSE OF CONFERENCE
VIEW PREVIOUS DAY
DAY ONE - JULY 25
DAY TWO - JULY 26
NEO SYNTH International House, 24 Holborn Viaduct, London EC1A 2BN
The server encountered an error.
Request received. Please allow some time for processing - You will receive a manual response within a few hours.
Your details will not be shared with a third party
Copyright © 2017| All content produced by: neo-synth ltd.